Biomarin Pharmaceutical Inc SEC filings BMRN
Biomarin Pharmaceutical Inc has 1,000 filings in SEC EDGAR's recent list, going back to Feb 2, 2017. Its latest annual report, Form ARS, was filed on Apr 21, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 2, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 2, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 6, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 30, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Other events
|
Sep 15, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 14, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Other events
|
Sep 1, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Aug 31, 2026 | Aug 30, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Aug 18, 2026 | Aug 17, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K/A |
Amended current report
Other events
|
Jul 13, 2026 | Apr 27, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 4, 2026 | Jun 2, 2026 |
| 8-K |
Current report
Results of operations
|
May 4, 2026 | May 4, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, New debt, Regulation FD disclosure
|
Apr 27, 2026 | Apr 27, 2026 |
| 8-K |
Current report
Other events
|
Apr 23, 2026 | Apr 23, 2026 |
| 8-K |
Current report
Other events
|
Mar 16, 2026 | Mar 16, 2026 |
| 8-K |
Current report
Results of operations
|
Feb 23, 2026 | Feb 23, 2026 |
| 8-K |
Current report
Material agreement, New debt, Regulation FD disclosure
|
Feb 12, 2026 | Feb 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 29, 2026 | Jan 29, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Jan 26, 2026 | Jan 26, 2026 |
| 8-K |
Current report
Results of operations
|
Jan 12, 2026 | Jan 12, 2026 |
| 8-K |
Current report
Other events
|
Dec 22, 2025 | Dec 19, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Dec 19, 2025 | Dec 19, 2025 |
| 8-K |
Current report
Officer or director change
|
Dec 17, 2025 | Dec 11, 2025 |
| 8-K |
Current report
Results of operations
|
Oct 27, 2025 | Oct 27, 2025 |
| 8-K |
Current report
Results of operations
|
Oct 7, 2025 | Oct 7, 2025 |
| 8-K |
Current report
Officer or director change
|
Aug 11, 2025 | Aug 5, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2025 | Aug 4, 2025 |
| 8-K |
Current report
Officer or director change
|
Aug 1, 2025 | Jul 30, 2025 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 22, 2025 | May 20, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
May 16, 2025 | May 16, 2025 |
| 8-K |
Current report
Results of operations
|
May 1, 2025 | May 1, 2025 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Mar 3, 2025 | Feb 25, 2025 |
| 8-K |
Current report
Officer or director change
|
Feb 24, 2025 | Feb 20, 2025 |
| 8-K |
Current report
Results of operations
|
Feb 19, 2025 | Feb 19, 2025 |
| 8-K |
Current report
Results of operations
|
Oct 29, 2024 | Oct 29, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 24, 2024 | Sep 24, 2024 |
| 8-K |
Current report
Material agreement, New debt
|
Sep 4, 2024 | Aug 28, 2024 |
| 8-K |
Current report
Exit or restructuring costs
|
Aug 28, 2024 | Aug 23, 2024 |
| 8-K |
Current report
Officer or director change
|
Aug 22, 2024 | Aug 16, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2024 | Aug 5, 2024 |
| 8-K |
Current report
Shareholder vote results
|
May 24, 2024 | May 21, 2024 |
| 8-K |
Current report
Exit or restructuring costs
|
May 14, 2024 | May 9, 2024 |
| 8-K |
Current report
Results of operations
|
Apr 24, 2024 | Apr 24, 2024 |
| 8-K |
Current report
Other events
|
Apr 23, 2024 | Apr 9, 2024 |
| 8-K |
Current report
Results of operations
|
Feb 22, 2024 | Feb 22, 2024 |
| 8-K |
Current report
Officer or director change
|
Jan 11, 2024 | Jan 5, 2024 |
| 8-K |
Current report
Material agreement, Officer or director change, Regulation FD disclosure
|
Dec 20, 2023 | Dec 20, 2023 |
| 8-K |
Current report
Officer or director change
|
Nov 3, 2023 | Oct 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 1, 2023 | Nov 1, 2023 |
| 8-K |
Current report
Results of operations
|
Jul 31, 2023 | Jul 31, 2023 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 30, 2023 | May 23, 2023 |
| 8-K |
Current report
Results of operations
|
Apr 26, 2023 | Apr 26, 2023 |
| 8-K |
Current report
Results of operations
|
Feb 27, 2023 | Feb 27, 2023 |
| 8-K |
Current report
Results of operations
|
Jan 11, 2023 | Jan 9, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Dec 21, 2022 | Dec 15, 2022 |
| 8-K |
Current report
Results of operations
|
Oct 26, 2022 | Oct 26, 2022 |
| 8-K |
Current report
Exit or restructuring costs
|
Oct 7, 2022 | Oct 6, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 12, 2022 | Sep 12, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 3, 2022 | Aug 3, 2022 |
| 8-K |
Current report
Shareholder vote results
|
May 31, 2022 | May 24, 2022 |
| 8-K |
Current report
Officer or director change
|
May 5, 2022 | May 5, 2022 |
| 8-K |
Current report
Results of operations
|
Apr 27, 2022 | Apr 27, 2022 |
| 8-K |
Current report
Results of operations
|
Feb 23, 2022 | Feb 23, 2022 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Feb 14, 2022 | Feb 14, 2022 |
| 8-K |
Current report
Officer or director change
|
Dec 15, 2021 | Dec 10, 2021 |
| 8-K |
Current report
Officer or director change
|
Nov 3, 2021 | Oct 29, 2021 |
| 8-K |
Current report
Results of operations
|
Oct 27, 2021 | Oct 27, 2021 |
| 8-K |
Current report
Results of operations
|
Jul 28, 2021 | Jul 28, 2021 |
| 8-K |
Current report
Material agreement, New debt
|
Jun 2, 2021 | May 28, 2021 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 1, 2021 | May 25, 2021 |
| 8-K |
Current report
Results of operations
|
Apr 29, 2021 | Apr 29, 2021 |
| 8-K |
Current report
Results of operations
|
Feb 25, 2021 | Feb 25, 2021 |
| 8-K |
Current report
Officer or director change
|
Feb 22, 2021 | Feb 17, 2021 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Dec 18, 2020 | Dec 15, 2020 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2020 | Nov 5, 2020 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 9, 2020 | Sep 9, 2020 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2020 | Aug 4, 2020 |
| 8-K |
Current report
Officer or director change
|
Jul 2, 2020 | Jun 29, 2020 |
| 8-K |
Current report
Shareholder vote results
|
Jun 1, 2020 | May 27, 2020 |
| 8-K |
Current report
New debt, Unregistered share sale, Other events
|
May 19, 2020 | May 19, 2020 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Other events
|
May 14, 2020 | May 11, 2020 |
| 8-K |
Current report
Results of operations
|
Apr 29, 2020 | Apr 29, 2020 |
| 8-K |
Current report
Officer or director change
|
Apr 22, 2020 | Apr 17, 2020 |
| 8-K |
Current report
Results of operations
|
Feb 26, 2020 | Feb 26, 2020 |
| 8-K |
Current report
Officer or director change
|
Feb 3, 2020 | Jan 28, 2020 |
| 8-K |
Current report
Results of operations
|
Oct 23, 2019 | Oct 23, 2019 |
| 8-K |
Current report
Results of operations
|
Aug 1, 2019 | Aug 1, 2019 |
| 8-K |
Current report
Officer or director change
|
Jul 10, 2019 | Jul 8, 2019 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 7, 2019 | Jun 4, 2019 |
| 8-K |
Current report
Results of operations
|
Apr 25, 2019 | Apr 25, 2019 |
| 8-K |
Current report
Results of operations
|
Feb 21, 2019 | Feb 21, 2019 |
| 8-K |
Current report
Results of operations
|
Jan 8, 2019 | Jan 7, 2019 |
| 8-K |
Current report
Results of operations
|
Oct 25, 2018 | Oct 25, 2018 |
| 8-K |
Current report
Material agreement, Agreement ended, New debt
|
Oct 23, 2018 | Oct 19, 2018 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Sep 24, 2018 | Sep 19, 2018 |
| 8-K |
Current report
Results of operations
|
Aug 2, 2018 | Aug 2, 2018 |
| 8-K |
Current report
Shareholder vote results
|
Jun 8, 2018 | Jun 5, 2018 |
| 8-K |
Current report
Results of operations
|
Apr 25, 2018 | Apr 25, 2018 |
| 8-K |
Current report
Results of operations
|
Feb 22, 2018 | Feb 22, 2018 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Nov 28, 2017 | Nov 21, 2017 |
| 8-K |
Current report
Results of operations
|
Oct 26, 2017 | Oct 26, 2017 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change
|
Oct 3, 2017 | Sep 28, 2017 |
| 8-K |
Current report
Material agreement, New debt, Other events
|
Aug 11, 2017 | Aug 7, 2017 |
| 8-K |
Current report
Results of operations
|
Aug 2, 2017 | Aug 2, 2017 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Jun 12, 2017 | Jun 6, 2017 |
| 8-K |
Current report
Results of operations
|
May 4, 2017 | May 4, 2017 |
| 8-K |
Current report
Material agreement, Other events
|
Apr 13, 2017 | Apr 12, 2017 |
| 8-K |
Current report
Results of operations
|
Feb 23, 2017 | Feb 23, 2017 |
Showing 108 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BMRN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Novato, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1048477
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.